A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma

A permanent cell line, S635c15, was derived from an anaplastic astrocytoma induced by the Schmidt-Ruppin strain of avian sarcoma virus (ASV) in a female F-344 rat. Persistent expression of the astrocytic differentiation protein, glial fibrillary acidic protein (GFAP), was detected both in cultured cells after 100 passages in vitro and in transplanted tumors. Subcutaneous and intracerebral transplantation of S635c15 cells in syngeneic rats resulted in a 100% tumor incidence and a reproducible mortality distribution. S635c15 cells formed discrete masses after subcutaneous injection but grew intracranially as infiltrative lesions. Tumor blood flow and blood-to-tissue transport studies yield comparable values to other rat glioma models; S635c15 intracranial tumors proved to be a homogeneous model with little variation within and between tumors with respect to morphology, GFAP expression, blood flow, and permeability. This cell line provides a GFAP-expressing brain tumor model that extends the use of autochthonous ASV-induced astrocytomas by allowing in vitro and in vivo studies. It may be useful for further studies in neurobiology and brain tumor biology, diagnosis, and therapy.     

9L/Fischer344与C6/Wistar两种大鼠脑胶质瘤模型的比较研究

目的探讨9L/Fischer344和C6/Wistar两种大鼠脑胶质瘤模型的对比研究。方法采用立体定向技术,大鼠脑内接种定量的肿瘤细胞建立模型,比较两种模型大鼠脑内肿瘤生长情况;采用免疫组织化学方法,比较两种模型脑内肿瘤局部细胞免疫反应情况。结果(1)9L/Fischer344大鼠脑内有肿瘤持续生长,而C6/Wistar大鼠脑内早期可见肿瘤生长,但肿瘤局部有大量淋巴细胞浸润,肿瘤周边血管呈现“淋巴细胞血管套”现象,后期脑内肿瘤逐渐消退、消失,仅见残留轨迹和含褐色素沉着的吞噬细胞;(2)9L/Fischer344肿瘤局部可见CD68阳性细胞,未见CD4、CD8阳性细胞,而C6/Wistar肿瘤局部CD68阳性细胞数量明显较9L模型多(P<0.01),并可见CD4、CD8阳性的淋巴细胞。结论9L/Fischer344模型稳定性高,重复性好,肿瘤局部T淋巴细胞浸润极少,是一种较为理想的脑胶质瘤免疫治疗研究的动物模型;C6/Wistar模型脑内肿瘤不能持续生长,脑内肿瘤可自发性消退,肿瘤局部T淋巴细胞浸润明显,存在较强的细胞免疫反应,可能是肿瘤的消退的原因,该模型不适合用于胶质瘤治疗,尤其是免疫治疗的实验研究。     

The 9LLUC/Wistar rat glioma model is not suitable for immunotherapy

The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9LLUC glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9LLUC/F344 rats, and tumor regression was found in some 9LLUC/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9LLUC/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9LLUC/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.     

Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred fischer rats

Summary The Schmidt-Ruppin strain of Rous sarcoma virus has been shown to induce neuroectodermal and mesenchymal tumors of the brain of inbred CDF Fischer rats. The inoculation of 10⁵ FFU of virus into the cerebrum of 2 day old rats was followed by 96% incidence of tumor growth after a latency period of 3 months. Twenty-four of twenty-five inoculated animals developed tumors, all of which were primary intracerebral neoplasms. They fell into three main groups: gliomas 60%, sarcomas 31%, gliosarcomas 9%. Of the 34 gliomas induced, 28 (84%) were astrocytic, and there was one oligodendroglioma, 2 mixed gliomas, and 3 ependymoma-like tumors. The advantages of this brain tumor model are a high glioma incidence, and a short induction time in a commercially available strain of inbred Fischer rats previously shown to be susceptible to the neuro-oncogenic action of resorptive chemical carcinogens.Supported by fellowships of the Max-Planck-GesellschaftUSPHS Grant CA-11898     

The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats.

The induction of intracranial neoplasms following the intracerebral inoculation of avian sarcoma virus (ASV) in neonatal mammals is well established. The present study demonstrates the susceptibility of adult rats and compares the incidence and morphology of tumors induced by a uniform inoculum of the Bratislava-77 strain of ASV in adult, neonatal, and fetal Fischer 344 rats. Post-inoculation mortality varied significantly between groups inoculated at 1, 10 and 100 days and was most precipitous in perinatally inoculated rats. Percentage of tumor induction declined from 100% among rats inoculated at 1 day of age to 50% among rats inoculated at 100 days of age. The mean number of tumors/animal was inversely proportional to the logarithm of the age at inoculation. A large majority of tumors in each group were glial; the remainder were mesenchymal and mixed glial and mesenchymal. Neuroglial tumors included: mixed gliomas with oligodendroglial and astrocytic elements; and gemistocytic, pilocytic, fibrillary, anaplastic and protoplasmic astrocytomas. Tumors induced in perinates were more heterogeneous in histological pattern while tumors induced in perinates were more heterogeneous in histological pattern while tumors induced in older animals tended to be purely astrocytic and of uniform cell type. Mesenchymal tumors occurred primarily in the meninges and were common among animals inoculated perinatally but were rare among animals inoculated as adults. No neuronal tumors were encountered even among rats inoculated as early as 16 days of gestation.     

Experimental brain tumor in adult mongrel cat

Small animal models such as the rat have serious limitations for multiple human scale instrumentation, surgical manipulations, and computerized tomographic (CT) evaluations, so that large animal models are required for the study using them. Although brain tumors induced with Rous sarcoma virus in neonatal beagle or adult monkey had been reported, these animals are very expensive ones for tumor research. A major drawback of virally induced brain tumor model is, moreover, the need for specialized viral facilities and safety precautions for laboratory personnel. In this paper, a cat glioma model implanted with C6 glioma cells derived from rats injected with N-nitrosomethylurea is reported. For an implantation dose of 5 x 10(5) cells/50 microliters, C6 glioma cells were suspended in modified Eagle medium supplemented with 10% fetal bovine serum and 0.5% agar. Twenty adult mongrel cats were injected with 5 x 10(5) C6 glioma cells intracerebrally. Implanted cats had brain tumors of about 10 mm in diameter with a yield of 80%. The mean survival was about 3 weeks after implantation. Tumors developed as spheroidal, hemorrhagic masses with central areas of necrosis and peripheral edema. They were located within the parenchyma of the implanted region. This tumor possessed many of the histological and radiological characteristics of human glioblastoma such as the following: Areas of hemorrhage and necrosis surrounded by pseudopallisading were observed within the tumor consisting of spindle-shaped cells with pleomorphic nuclei. A mass lesion with ring or garland-like enhancement surrounded by brain edema was shown on the CT scans.(ABSTRACT TRUNCATED AT 250 WORDS)     

Relation between distribution of DNA synthesizing cells and blood flow and glucose metabolism in Rous sarcoma virus-induced rat brain tumors

The correlations between blood flow or glucose metabolism and distribution of DNA synthesizing cells were simultaneously investigated in the same rat brain tumors using autoradiographic technique and immunoperoxidase stain. Two rat brain tumor strains (A and B) induced by Rous sarcoma virus were used. A suspension of 1 X 10(4) rat brain tumor cells was stereotactically implanted into the right basal ganglia of syngenic Fischer 344/Du Crj rats. The tumor strain A bearing rats died 12.0 +/- 1.8 days and the tumor strain B bearing rats died 17.6 +/- 1.3 days after the tumor implantation. Blood flow and glucose metabolism were measured with 14C-iodoantipyrine and 14C-2-deoxy-D-glucose autoradiography. All rats also received a 1-h i.v. infusion of BrdU, 5-20 mg, at the autoradiographic procedure. The immunoperoxidase staining for BrdU (Avidin Biotin peroxidase complex method) and other conventional stainings were performed in the sections alternating with the autoradiographic sections. BrdU-positive nuclei (S-phase cells) were heterogeneously distributed and labeling index ranged from less than 1% to more than 40% in the tumors. Neoplastic vessels tended to be distributed in the peripheral part of the tumor and were surrounded with S-phase cells in a part of the tumor. The blood flow was heterogeneously distributed in the tumor and the average blood flow reduced to about 50% in the tumor strain A and to about 60% in the tumor strain B, respectively in comparison with contralateral cortex. The distribution of blood flow did not correlate with the distribution of S-phase cells nor the distribution of neoplastic vessels.(ABSTRACT TRUNCATED AT 250 WORDS)     

The morbidity and mortality of brain tumors. A perspective on recent advances in therapy

This article reviews current morbidity and mortality statistics for the major classes of primary brain tumors including malignant astrocytoma, glioblastoma, low-grade astrocytoma, oligodendroglioma, meningioma, and other benign tumors and metastatic tumors. Innovations in therapy are discussed for surgery, radiation, chemotherapy, and such newer areas as hyperthermia, immunotherapy, and phototherapy.     

9L/F344与C6/Wistar大鼠脑胶质瘤模型局部细胞免疫反应的比较研究

目的对9L/F344和C6/Wistar两种大鼠脑胶质瘤模型肿瘤局部细胞免疫反应情况进行比较研究.方法采用立体定向技术建立两种大鼠脑胶质瘤模型.定期处死大鼠取脑,常规石蜡切片,苏木精-伊红染色行肿瘤组织病理学观察;冰冻切片,行免疫组织化学染色,观察大鼠脑内肿瘤淋巴细胞浸润情况.结果两种模型脑内肿瘤组织病理学均具有恶性脑胶质瘤的特点.C6/Wistar模型肿瘤周边和瘤内可见大量单个核细胞浸润,肿瘤周边血管呈现"淋巴细胞血管套"现象.肿瘤局部CD68、CD4、CD8阳性的淋巴细胞在C6/Wistar模型中多见;9L/F344模型中可见CD68阳性细胞,但数量较C6模型中为少,P＜0.01,且未见CD4、CD8阳性细胞.结论9L/F344模型肿瘤局部T淋巴细胞浸润少.C6/Wistar模型肿瘤周边及瘤内淋巴细胞浸润明显,存在强烈的细胞免疫反应,不适用于胶质瘤免疫治疗的实验研究.     

Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma

S69-c15 is a highly immunogenic cell line derived from an avian sarcoma virus (ASV)-induced astrocytoma in F-344 rats. Monoclonal antibody (Mab) production was attempted by fusing F-344 rat splenocytes and mouse P3 X 63/Ag8.653 myeloma cells after a syngeneic immunization protocol. 336 fusion clones were screened by cell surface radioimmunoassay (CS-RIA) against the immunizing line S69-c15, rat kidney fibroblast line S203-c11 and Walker rat carcinoma line. Mabs 7G4, 9F1, 10E3 and 10E7 which reacted only with S69-c15 were chosen. Further analysis demonstrated that these Mabs reacted only with rat (13/23 astrocytomas, 2/4 gliomas, 1/11 neurinomas) or mouse (2/10 astrocytomas) neurogenic tumor cells induced by both viral and chemical agents. Reciprocal competition assays suggested that 7G4, 9F1 and 10E3 recognized the same epitope and that 10E7 reacted with a spatially close determinant. Antigen activity could not be found in adult rat tissues (brain, heart, lung, liver, kidney, spleen, thymus, intestine, muscle and peripheral nerve) and fetal brain (8, 12, 20 days gestation) by either absorption analysis or tissue staining. Preliminary characterization indicated that the epitope may be polypeptide-associated. Further antigen purification and tumor localization can be attempted with these Mabs.     

IRRADIATION AND BCNU EFFECTS IN THE STROMA IN A RAT TRANSPLANTED GLIOMA MODEL: ANALYSIS OF CEREBRAL TUMOR BED EFFECT

F-344 rats were treated with whole-brain fractionated or unfractionated 137Cs at several time intervals up to 6 weeks before they received intracerebral grafts of an ethylnitrosourea-induced rat astrocytoma (36B-10). Rats treated with a single dose of 18 Gy at 3- and 2 week intervals prior to tumor implantation died earlier than unirradiated control tumor recipients (P less than 0.05, log rank sum test). Delivered 2 weeks prior to tumor grafting single doses of 10, 15, and 20, but not 5 Gy also reduced animal life span (P less than 0.05). Similarly, a total dose of 38 but not 28.5, 19, or 9.5 Gy, each delivered in five daily fractions 2 1/2 weeks before tumor grafting, shortened survival (P less than 0.05). Chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea (13.3 mg/kg) alone or in combination with a single-dose of irradiation of 18 Gy 3 weeks preceding transplantation showed no effect on animal survival. Unirradiated control tumors demonstrated sheets of densely-packed isomorphic astrocytes, perivascular brain parenchymal invasion, sparse, thin-walled vasculature, frequent mitoses, but little necrosis or hemorrhage. The tumors of rats irradiated before transplantation showed large areas of confluent necrosis associated with microvascular thrombosis, edema, and multifocal acute hemorrhages. These survival results and morphological changes indicate that the cerebral tumor bed effect involves early animal death and extensive morphological changes in the tumors; and they suggest that tumor cell death in irradiated brain tumors may, in part, result from radiation-induced vascular injury.     

Effects of treatment on long-term survivors with malignant astrocytomas

We reviewed the records of 160 consecutive patients with glioblastoma and anaplastic astrocytoma to evaluate the long-term consequences of radiation therapy and chemotherapy. We defined long-term survivors as those patients with glioblastoma or anaplastic astrocytoma who lived at least 100% longer than median survival of historical controls, for example, 2 years for patients with glioblastoma and 4 years for patients with anaplastic astrocytoma. There were 9 (5.6%) long-term survivors. Three (30%) became demented and died without evidence of tumor recurrence. One, after survival of 10 years, died of tumor recurrence. Of the remaining survivors, 2 (22%) have significantly impaired short-term memory function and other neurological deficits such as gait apraxia. Three (30%) can function independently. It is likely but cannot be proved that it is radiotherapy and not chemotherapy that is the causal factor of this dismal therapeutic outcome. Our study suggests restraint in the use of radiotherapy for patients with brain tumors that have more favorable prognoses than glioblastomas and anaplastic astrocytomas, such as low-grade astrocytomas and oligodendrogliomas.     

Activities of pyrimidine nucleoside phosphorylase in brain tumors and antitumor effect of 5'-DFUR

Activities of pyrimidine nucleoside phosphorylase in brain tumors were measured and their relationship to a clinical course of the patients was investigated. Pyrimidine nucleoside phosphorylase is said to exist more quantitatively in malignant tumors such as Sarcoma 180, Ehrlich ascites carcinoma, Walker 256, and hepatoma, and very little in normal tissues. In brain tumors the activities were measured by bioassay and compared to that of Sarcoma 180. When the activity of Sarcoma 180 was expressed to be 100%, those of brain tumors were as follows: ten cases of normal brain less than 8.5; six cases of glioblastoma 39.3 +/- 30.7; five cases of astrocytoma 22.0 +/- 13.8; five cases of meningioma 22.4 +/- 13.7; two cases of oligodendroglioma 8.1 and 11.3; two cases of sarcoma 94.3 and 145.4; chordoma 48.0; ependymoblastoma 3.7; plexus papilloma 22.5; parotid cancer 43.4; ten cases of metastatic brain tumors from lung cancer 61.5 +/- 41.6; two cases from breast cancer 28.0 and 68.8; that from thyroid cancer 10.0; that from gastric cancer 13.5; malignant melanoma 77.2. In 12 cases of gliomas (glioblastoma, astrocytoma, oligodendroglioma) the mean activity was highest in glioblastoma (39.3), followed by astrocytoma (22.0) and oligodendroglioma (9.7). The postoperative survival time became shorter in gliomas with the higher activities. In metastatic brain tumors from lung, breast, and gastric cancer, the average time from the diagnosis of primary cancer to brain metastasis was shorter in cases with high activities and longer in cases with low activities.(ABSTRACT TRUNCATED AT 250 WORDS)     

Adoptive immunotherapy in patients with medulloblastoma by LAK cells

Medulloblastoma is one of the most popular malignant brain tumors in children. It accounts for about 15% of all pediatric brain tumors. Radiochemotherapy has prolonged the 5-year survival rate up to 60-85% for patients with medulloblastoma. But the conventional therapy is not so effective to recurrent cases, especially with meningeal dissemination, and generally fatal. There remains a big problem of the neurotoxicity to infants in a growth process under the whole-neuraxis irradiation and chemotherapy. Aiming to relieve the radiation and antitumor drugs, adoptive immunotherapy is greatly expectant. We have had clinical trials of adoptive immunotherapy for 8 patients with medulloblastoma by lymphokine-activated killer (LAK) cells. They were from 2-9 years in age and had cerebrospinal fluid (CSF) dissemination of the tumors. All patients underwent the whole-neuraxis irradiation and chemotherapy. After they had CSF dissemination, they were submitted to an adoptive transfer of allogeneic LAK cells. LAK cells were induced from peripheral blood lymphocytes (PBL) of their relatives with human recombinant interleukin-2. 3-15 x 10(9) LAK cells were transferred intrathecally in 2-3 months. In 3 of 8 patients, neurological signs were improved and malignant cells had never been detected on CSF cytology after the adoptive immunotherapy. One among these 3 patients showed complete response in 20 months. Thus, this is an attractive treatment for patients with medulloblastoma, especially with CSF dissemination, which cannot be cured by current therapeutic intervention.     

Adenovirus-mediated gene therapy of experimental gliomas

The efficacy of adenovirus (ADV)-mediated gene therapy to treat brain tumors was tested in a syngeneic glioma model. Tumor cells were transduced in situ with a replication-defective ADV carrying the herpes simplex virus thymidine kinase (HSV-tk) gene controlled by the Rous sarcoma virus promoter. Expression of the HSV-tk gene enables the transduced cell to convert the drug ganciclovir to a form that is cytotoxic to dividing cells. Tumors were generated in Fischer 344 rats by stereotaxic implantation of 9L gliosarcoma cells into the caudate nucleus. Eight days later, the tumors were injected either with the ADV carrying the HSV-tk (ADV-tk) gene or a control ADV vector containing the β-galactosidase (ADV-βgal) gene and the rats were treated with either ganciclovir or saline. Tumor size was measured 20 days after implantation of 9L cells or at death. Rats treated with ADV-βgal and ganciclovir or with ADV-tk and saline had large tumors. No tumors were detected in animals treated with ADV-tk and with ganciclovir at doses ≥80mg/kg. An infiltrate of macrophages and lymphocytes at the injection site in animals treated with ADV-tk and ganciclovir indicated an active local immune reaction. In survival studies, all animals treated with ADV-tk and ganciclovir have remained alive longer than 80 and up to 120 days after tumor induction whereas all untreated animals died by 22 days. These results demonstrate that ADV-mediated transfer of HSV-tk to glioma cells in vivo confers sensitivity to ganciclovir, and represents a potential method of treatment of brain tumors. © 1994 Wiley-Liss, Inc.     

Study on adoptive immunotherapy for experimental brain tumor

Adoptive immunotherapy for the experimental murine brain tumor has been investigated using LAK cells generated in vitro from normal spleen cells with IL-2 and immune spleen cells from Fischer rats immunized against syngenic gliosarcoma, T9. IL-2 inhibitor(s) activity in serum was also studied. LAK cells and immune spleen cells were adoptively transferred to the rats intravenously or intratumorally on the 7th day after the inoculation of T9 into the right basal ganglia. Then the survival rate and necrotic foci were compared between the groups treated with those cells and the control. The survival rate of the groups treated with LAK cells was significantly higher than that of the control (administrated intravenously; P less than 0.01, administrated intratumorally; P less than 0.05). But the treatment with immune spleen cells was not effective. The incidence and area of necrotic foci in the tumors treated with LAK cells were greater than those of the others. Microautoradiography was also performed using 3H-TdR labeled LAK cells, which were administrated intravenously to the model. It was revealed that LAK cells accumulated in lung shortly after the administration, then in liver and spleen, especially in the white pulp. IL-2 inhibitor activity of the sera from the tumor-bearers was greater than that of normal rats, while it was depressed markedly by cyclophosphamide (60 mg/kg i.p.). In conclusion, the adoptive transfer of LAK cells can be one of the effective and attractive treatments of the brain tumor. In order to make immunotherapy more effective it should be necessary to clarify the nature of IL-2 inhibitor(s).     

Brain tumors of early infants.

The authors describe their experience with ten cases of brain tumors in children in whom the onset of symptoms occurred within the first year of life, but who were operated on when they were 2 months to 4 years of age. The series includes 5 gliomas (4 supratentorial, 1 cerebellar; 3 astrocytomas, 1 spongioblastoma, 1 ependymoblastoma), 2 teratomas of the lateral ventricle, and 3 single cases of third ventricle choroid plexus papilloma, temporal lobe sarcoma, and a parasellar craniopharyngioma. Six cases were partially removed, one of them was shunted. Only biopsy was carried out in two, one of which was shunted. The only case of radical removal was a lateral ventricle teratoma; this patient died at operation. Nine patients survived at surgery, three of whom are alive on the 3rd, 4th, and 7th postoperative year. There were two late deaths: one at 2 years (lateral ventricle astrocytoma, which was only biopsied) and one at 7 years and 3 months (spongioblastoma) following surgery. This series from a 40-year period (1933-1973) represents 0.4% of 2,832 brain tumors and 1.9% of 528 brain tumors in the pediatric age. The authors emphasize the need to treat brain tumors in early infancy and insist on the use of radiotherapy and chemotherapy when the lesions are not radically removed at surgery.     

Detection of experimentally induced brain tumors in rats using high resolution computed tomography

OBJECTIVE: The feasibility of high resolution CT imaging for evaluating experimentally-induced brain tumors in rats was assessed. METHODS: The gliosarcoma cell line (9 L/lacZ) was inoculated in 34 male Fischer 344 rats and CT studies were performed prior to and at 4, 7, 9, 12 and 14 days post-tumor cell implantation. Brain imaging pre- and post-contrast was performed and correlated with autopsy findings. RESULTS: Tumors were identified by CT in 19 of the 34 animals after contrast administration and their presence was confirmed at autopsy. Tumors were present at autopsy and not identified by CT scanning in eight additional animals and in the remaining seven animals, the CT scan was normal and no tumors were present at autopsy. The sensitivity and specificity of CT scanning with contrast in detecting tumors in this rat model of gliosarcoma was 70 and 100%, respectively. CONCLUSION: The improved CT technology currently available can be used to identify and follow tumor burden in a rat model of gliosarcoma, and be a good tool to utilize in determining treatment outcomes experimentally, especially when MR imaging is not available.     

The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption

The limited effect of chemotherapy on malignant brain tumors has been related to tumor cell insensitivity to the drugs and to their ineffectual delivery to the tumor. The studies by Groothuis and Neuwelt et al have shown that the studies of tumor vessel permeability show considerable variability in different areas of tumors and between different tumor models. The present studies used the 9L gliosarcoma model in Fischer 344 rats to evaluate the increase of tumor vessel permeability by osmotic BBB opening on drug delivery to the tumor, brain adjacent to tumor (BAT), and brain distant to tumor using cis-diamminedichloroplatinum (CDDP) as a chemotherapeutic agent which was water soluble and rarely permeable to BBB. In addition the difference of delivery to normal brain and tumor tissue were studied on intravenous or intracarotid administration of cisplatin with or without intracarotid infusion of graded (20%, 25%) hyperosmolar mannitol. Evans blue, which binds to plasma albumin, was used to provide a visual marker of BBB opening. 20% or 25% hyperosmolar mannitol infusion to right internal carotid artery for BBB disruption was done at 0.12 ml/sec for 30 sec with controlled respiration after temporally clipping of right common carotid artery. Then cis-diamminedichloroplatinum (CDDP) was infused at 0.5 mg/ml/100 gr (body weight). In control studies isotonic saline instead of mannitol was infused to intracarotid artery at identical rate and volume. In 14 9L gliosarcoma bearing rats and 3 normal rats cis-diamminedichloroplatinum (CDDP) delivery to tumor and normal brain.(ABSTRACT TRUNCATED AT 250 WORDS)     

Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas

Adenosine was infused intravenously at 10 mumol/(kg.min) into athymic ("nude") rats with intracerebral D-54MG xenotransplanted brain tumors, in an attempt to increase tumor blood flow. Cerebral blood flow (F) was measured with 14C-iodoantipyrine and quantitative autoradiography. Mean arterial blood pressure was 95 +/- 9.4 (SE) mm Hg in the adenosine group and 112 +/- 6.0 mm Hg in the controls. Averaged mean whole tumor F was significantly higher in adenosine-treated brain tumors (117.6 +/- 20.8 ml/[hg.min]) than in controls (62.2 +/- 9.7 ml/[hg.min]). Regionally, there were significant increases of F in tumor periphery and brain around tumor, but not in tumor center or any tumor-free brain regions. Focal values of F less than 5 ml/(hg.min) were present in some necrotic regions of adenosine-treated tumors. These results, obtained in unanesthetized rats with transplanted gliomas from a human cell line, confirm our earlier observations in avian sarcoma virus-induced brain sarcomas in dogs, and suggest that adenosine or perhaps other vasodilators could be used to selectively increase the delivery of lipid-soluble chemotherapeutic drugs to brain tumors.